Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2025

Aug 14, 2025

BUY
$2.97 - $11.38 $10,406 - $39,875
3,504 Added 11.57%
33,785 $379,000
Q1 2025

May 14, 2025

BUY
$4.57 - $8.63 $138,384 - $261,325
30,281 New
30,281 $138,000

Others Institutions Holding VERV

About Verve Therapeutics, Inc.


  • Ticker VERV
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 59,942,300
  • Market Cap $667M
  • Description
  • Verve Therapeutics, Inc., a genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases. Its lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver. The company also engages in the development of ANGPTL3 program t...
More about VERV
Track This Portfolio

Track Sei Investments CO Portfolio

Follow Sei Investments CO and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Sei Investments CO, based on Form 13F filings with the SEC.

News

Stay updated on Sei Investments CO with notifications on news.